星空体育官方入口网站网址大全-登录入口官网

#疗效和安全性研究#

12篇内容 | 659人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1798770, encodeId=b2c21e98770f4, content=<a href='/topic/show?id=3b62e0402fd' target=_blank style='color:#2F92EE;'>#疗效和安全性研究#</a>, objectTitle=Neurology：难治性局灶性癫痫患者辅助性塞诺巴胺的长期疗效和安全性研究, objectType=article, longId=738700, objectId=3adfe3870050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3adfe3870050, replyNumber=0, likeNumber=80, createdTime=2023-03-22, rootId=0, userName=changhe713, userId=56ea361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3adfe3870050, moduleTitle=Neurology：难治性局灶性癫痫患者辅助性塞诺巴胺的长期疗效和安全性研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=3adfe3870050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1798768, encodeId=42701e987681e, content=<a href='/topic/show?id=3b62e0402fd' target=_blank style='color:#2F92EE;'>#疗效和安全性研究#</a>, objectTitle=Sci Rep：52周的Dupilumab治疗中重度特应性皮炎的长期疗效和安全性研究, objectType=article, longId=299023, objectId=2d572990238b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d572990238b, replyNumber=0, likeNumber=86, createdTime=2023-02-02, rootId=0, userName=changhe713, userId=56ea361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d572990238b, moduleTitle=Sci Rep：52周的Dupilumab治疗中重度特应性皮炎的长期疗效和安全性研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2d572990238b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1798769, encodeId=c6a91e987695e, content=<a href='/topic/show?id=3b62e0402fd' target=_blank style='color:#2F92EE;'>#疗效和安全性研究#</a>, objectTitle=2022 ASCO：一种新型抗 PD-1 抗体Serplulimab，化疗疗效和安全性研究的3期研究, objectType=article, longId=728406, objectId=362fe28406f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=362fe28406f5, replyNumber=0, likeNumber=83, createdTime=2022-11-05, rootId=0, userName=changhe713, userId=56ea361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=362fe28406f5, moduleTitle=2022 ASCO：一种新型抗 PD-1 抗体Serplulimab，化疗疗效和安全性研究的3期研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=362fe28406f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1798767, encodeId=f7561e987675f, content=<a href='/topic/show?id=3b62e0402fd' target=_blank style='color:#2F92EE;'>#疗效和安全性研究#</a>, objectTitle=Prostate Cancer：纳米体多烯紫杉醇脂悬液在转移去势抵抗性前列腺癌中的多中心、回顾性疗效和安全性研究, objectType=article, longId=205674, objectId=19872056e42f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19872056e42f, replyNumber=0, likeNumber=94, createdTime=2021-08-16, rootId=0, userName=changhe713, userId=56ea361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19872056e42f, moduleTitle=Prostate Cancer：纳米体多烯紫杉醇脂悬液在转移去势抵抗性前列腺癌中的多中心、回顾性疗效和安全性研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=19872056e42f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1798765, encodeId=3ea51e9876509, content=<a href='/topic/show?id=3b62e0402fd' target=_blank style='color:#2F92EE;'>#疗效和安全性研究#</a>, objectTitle=Allergy：SQ屋尘螨舌下免疫治疗药片疗效和安全性研究, objectType=article, longId=147463, objectId=6bc014e4637e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6bc014e4637e, replyNumber=0, likeNumber=99, createdTime=2018-12-30, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6bc014e4637e, moduleTitle=Allergy：SQ屋尘螨舌下免疫治疗药片疗效和安全性研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6bc014e4637e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1798766, encodeId=b5b61e98766db, content=<a href='/topic/show?id=3b62e0402fd' target=_blank style='color:#2F92EE;'>#疗效和安全性研究#</a>, objectTitle=坦度螺酮增效治疗高焦虑状态的抑郁症患者的疗效和安全性研究, objectType=article, longId=150200, objectId=2132150200f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2132150200f3, replyNumber=0, likeNumber=113, createdTime=2019-03-31, rootId=0, userName=changhe713, userId=56ea361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2132150200f3, moduleTitle=坦度螺酮增效治疗高焦虑状态的抑郁症患者的疗效和安全性研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=2132150200f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1798764, encodeId=79ca1e9876451, content=<a href='/topic/show?id=3b62e0402fd' target=_blank style='color:#2F92EE;'>#疗效和安全性研究#</a>, objectTitle=J Ocul Pharmacol Ther：布林酰胺1％和溴莫尼定0.2％固定组合在正常眼压性青光眼中的疗效和安全性研究, objectType=article, longId=125640, objectId=89da12564094, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=89da12564094, replyNumber=0, likeNumber=97, createdTime=2018-05-14, rootId=0, userName=changhe713, userId=56ea361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=89da12564094, moduleTitle=J Ocul Pharmacol Ther：布林酰胺1％和溴莫尼定0.2％固定组合在正常眼压性青光眼中的疗效和安全性研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=89da12564094)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1798762, encodeId=9eb71e9876202, content=<a href='/topic/show?id=3b62e0402fd' target=_blank style='color:#2F92EE;'>#疗效和安全性研究#</a>, objectTitle=JCO ：Nivolumab+Ipilimumab联合治疗黑色素瘤的疗效和安全性研究, objectType=article, longId=111056, objectId=508e111056bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=508e111056bc, replyNumber=0, likeNumber=74, createdTime=2018-06-11, rootId=0, userName=changhe713, userId=56ea361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=508e111056bc, moduleTitle=JCO ：Nivolumab+Ipilimumab联合治疗黑色素瘤的疗效和安全性研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=508e111056bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1798763, encodeId=ac241e987632e, content=<a href='/topic/show?id=3b62e0402fd' target=_blank style='color:#2F92EE;'>#疗效和安全性研究#</a>, objectTitle=JAMA Surg：口内镜甲状腺前庭切除术的疗效和安全性研究, objectType=article, longId=112273, objectId=503f1122e3b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=503f1122e3b3, replyNumber=0, likeNumber=86, createdTime=2018-01-28, rootId=0, userName=changhe713, userId=56ea361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=503f1122e3b3, moduleTitle=JAMA Surg：口内镜甲状腺前庭切除术的疗效和安全性研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=503f1122e3b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1798761, encodeId=e7431e98761dc, content=<a href='/topic/show?id=3b62e0402fd' target=_blank style='color:#2F92EE;'>#疗效和安全性研究#</a>, objectTitle=JACC：经皮自膨式主动脉瓣置换术的疗效和安全性研究, objectType=article, longId=108439, objectId=a54a108439b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a54a108439b1, replyNumber=0, likeNumber=110, createdTime=2017-12-12, rootId=0, userName=changhe713, userId=56ea361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a54a108439b1, moduleTitle=JACC：经皮自膨式主动脉瓣置换术的疗效和安全性研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a54a108439b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1798760, encodeId=df3c1e98760c4, content=<a href='/topic/show?id=3b62e0402fd' target=_blank style='color:#2F92EE;'>#疗效和安全性研究#</a>, objectTitle=Diabetes Care：利拉鲁肽治疗1型糖尿病的疗效和安全性研究（ADJUNCT ONE）, objectType=article, longId=77897, objectId=becde7897ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=becde7897ae, replyNumber=0, likeNumber=81, createdTime=2017-06-16, rootId=0, userName=changhe713, userId=56ea361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=becde7897ae, moduleTitle=Diabetes Care：利拉鲁肽治疗1型糖尿病的疗效和安全性研究（ADJUNCT ONE）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=becde7897ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1798759, encodeId=59ac1e9875946, content=<a href='/topic/show?id=3b62e0402fd' target=_blank style='color:#2F92EE;'>#疗效和安全性研究#</a>, objectTitle=Diabetes Care：利拉鲁肽治疗1型糖尿病的疗效和安全性研究（ADJUNCT TWO）, objectType=article, longId=77886, objectId=f8ffe7886fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8ffe7886fc, replyNumber=0, likeNumber=102, createdTime=2017-05-20, rootId=0, userName=changhe713, userId=56ea361, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8ffe7886fc, moduleTitle=Diabetes Care：利拉鲁肽治疗1型糖尿病的疗效和安全性研究（ADJUNCT TWO）, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=f8ffe7886fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

疗效和安全性研究

2020-05-29

changhe713 (审核中...)

前往app查看评论内容

#疗效和安全性研究#

Neurology：难治性局灶性癫痫患者辅助性塞诺巴胺的长期疗效和安全性研究

2023-03-22

changhe713 (审核中...)

前往app查看评论内容

#疗效和安全性研究#

Sci Rep：52周的Dupilumab治疗中重度特应性皮炎的长期疗效和安全性研究

2023-02-02

changhe713 (审核中...)

前往app查看评论内容

#疗效和安全性研究#

2022 ASCO：一种新型抗 PD-1 抗体Serplulimab，化疗疗效和安全性研究的3期研究

2022-11-05

changhe713 (审核中...)

前往app查看评论内容

#疗效和安全性研究#

Prostate Cancer：纳米体多烯紫杉醇脂悬液在转移去势抵抗性前列腺癌中的多中心、回顾性疗效和安全性研究

2021-08-16

柳叶一刀 (审核中...)

前往app查看评论内容

#疗效和安全性研究#

Allergy：SQ屋尘螨舌下免疫治疗药片疗效和安全性研究

2018-12-30

changhe713 (审核中...)

前往app查看评论内容

#疗效和安全性研究#

坦度螺酮增效治疗高焦虑状态的抑郁症患者的疗效和安全性研究

2019-03-31

changhe713 (审核中...)

前往app查看评论内容

#疗效和安全性研究#

J Ocul Pharmacol Ther：布林酰胺1％和溴莫尼定0.2％固定组合在正常眼压性青光眼中的疗效和安全性研究

2018-05-14

changhe713 (审核中...)

前往app查看评论内容

#疗效和安全性研究#

JCO ：Nivolumab+Ipilimumab联合治疗黑色素瘤的疗效和安全性研究

2018-06-11

changhe713 (审核中...)

前往app查看评论内容

#疗效和安全性研究#

JAMA Surg：口内镜甲状腺前庭切除术的疗效和安全性研究

2018-01-28

changhe713 (审核中...)

前往app查看评论内容

#疗效和安全性研究#

JACC：经皮自膨式主动脉瓣置换术的疗效和安全性研究

2017-12-12

changhe713 (审核中...)

前往app查看评论内容

#疗效和安全性研究#

Diabetes Care：利拉鲁肽治疗1型糖尿病的疗效和安全性研究（ADJUNCT ONE）

2017-06-16

changhe713 (审核中...)

前往app查看评论内容

#疗效和安全性研究#

Diabetes Care：利拉鲁肽治疗1型糖尿病的疗效和安全性研究（ADJUNCT TWO）

2017-05-20

科室
- - 订阅+
  - 更多科室
工具
服务